Galectin Therapeutics Inc. · NASDAQ:GALT

Galectin Therapeutics — Investor Presentation (March 2013)

35 slides from Galectin Therapeutics's investor presentation, Mar 11, 2013

  1. Slide 1: Galectin Therapeutics Corporate Summary

    Exhibit 99.1 Galectin Corporate March NASDAQ: www.galectintherapeutics.com 11, Therapeutics 2013 Summary GALT

  2. Slide 2: Forward Looking Statements

    Forward Galectin This looking “estimate,” in market expectations a not those of benefits drugs, and our place © timely 2013 the any be continuing effective. presentation undue statements. that of as able opportunities statements Galectin fashion, of Therapeutics Looking our the are our “could,” tore

  3. Slide 3: What Galectin Therapeutics Does

    What Clinical Galectin Currently GR-MD-02 GM-CT-01 © 2013We stage Galectin Therapeutics proteins in Dotargeting for clinical biopharmaceutical the Therapeutics are indication trials cancer, important withenhance of2NASDAQ:GALT NASH compounds incompany the development ability (Fattytargeting of Liver

  4. Slide 4: Investment Highlights

    Investment Galectin Proprietary First Complex GR-MD-02: GM-CT-01: Validated Pre-clinical Large NASH Enhancing Intellectual Strong Sole No Experienced Management © 2013 licenses in ownership Market and patent class, Galectin Therapeutics carbohydrate Science liver the Property models Compounds Highli

  5. Slide 5: Key Corporate Facts

    Key Galectin Trading Corporate Stock Shares Daily Market Revenue Debt Cash 2013 Enterprise Fiscal Accounting © 2013 Facts (9-30-12) Volume Estimated & Price Year Capitalization Outstanding Galectin Equivalents Symbol Therapeutics TTM Headquarters Value Ends Firm (3-6-2013); (50-day N/A $0 Cash Nasda

  6. Slide 6: Science, Liver Fibrosis, Cancer Therapy

    Science Galectin Liver Immune Mechanism Regulatory Competitive © 2013Fibrosis Galectin of Enhancement Therapeutics Function Inhibitors Galectins and of Positioning Action Clinical Therapeutics in Plan Cancer NASDAQ:GALT Therapy 6

  7. Slide 7: Galectins Are Critical Participants in Disease Pathogenesis

    Galectin Secreted Bind Modulate Promote Markedly 1. 2. 3. GALECTINS Galectin-3 *Secreted For © 2013 Inflammation Fibrosis Cancer more to cell Galectin Therapeutics Proteins cell-cell cell-matrix Galectin detail Increased cell in issurface small most PROMOTE signaling on Therapeutics interactions Are

  8. Slide 8: Galectin Inhibitors as a Class of Pathology Modulators

    CONFIDENTIAL Galectin Novel Strongest Binding Low Two Discovery © 2013 classes toxicity complex Galectin to Inhibitors: Proteins Inhibitor binding program galectins potential of compounds carbohydrate Therapeutics toA underway disrupts galectin-3, New as a Class carbohydrate under function drugs to

  9. Slide 9: Regulatory Status

    Regulatory GM-CT-01 CONFIDENTIAL IMPD Has IND GR-MD-02 Pharmacology, GMP Received For © 2013 more for submitted been API foruse Galectin use on and OK shown Status incompounds in from GMP combination January pharmacokinetics, melanoma Therapeutics generally of FDA drug Drugs 2013 toproduct and proce

  10. Slide 10: Liver Fibrosis

    Science Galectin Liver Immune Mechanism Regulatory Competitive © 2013Fibrosis Galectin of Enhancement Function Inhibitors Galectins and of Positioning Action Clinical Therapeutics in Plan Cancer NASDAQ:GALT Therapy 10

  11. Slide 11: Galectin-3 Is a Critical Protein Target for Fibrosis Therapy

    Fibrosis Galectin Galectin-3 To © 2013 reviewGalectin due inhibitors data Is to is produced essential also A and Critical toxin Therapeutics critical reverse literature exposure Protein in infor mice large experimental fibrosis inTarget NASDAQ:GALT for or amounts more fatty theindetail For developme

  12. Slide 12: NASH: No Approved Therapy, Multi-Billion Dollar Market

    NASH The No While Transplants Wait Death Cirrhosis *NASH: #Deaths ##Prevalence &Prevalence ©*Performed 2013 Prevalence approved ONLY List there From and 9-15 Galectin in (17,000**) (400,000##) current Liver 1998 are (6,291*) Cirrhosis in Million& in medical in in US US treatments Therapeutics Fibros

  13. Slide 13: GR-MD-02 Eliminated Fibrosis in a Mouse Model of NASH

    Liver Vehicle GR-MD-02 Quantitative NAFLD Sirius © 2013Comparison Collagen red-positive Activity x200 Galectin markedly x200 Assessment Comparison score Therapeutics area improved 76 (%) of 5 41.25 NASH 3NASDAQ:GALT NASH 2 1.00 1 Activity 0 P<0.01 0.75 activity Quantitative 0.50 Vehicle score 13 0.2

  14. Slide 14: Treatment with GR-MD-02 Markedly Reduces Galectin-3 in NASH Mice

    Treatment Immunohistochemistry © GR-MD-02 x200 Vehicle 142013 Galectin with GR-MD-02 Therapeutics for detection Markedly NASDAQ:GALT of Reduces Galectin-3 Galectin-3 (Galectin-3 in NASH detected Micewith brown stain)

  15. Slide 15: GR-MD-02 Effectively Treats Toxin-Induced Liver Fibrosis in Rats

    Liver Treatment Galectin © 152013fibrosis Galectin Therapeutics Inhibitor with induced vehicle GR-MD-02 Therapeutics GR-MD-02 inData alone all for rats Effectively for four NASDAQ:GALT byfour injection weeks weeks Treats shows of (Control) chemical Toxin-Induced dramatic shows toxin regression robus

  16. Slide 16: Targeting Advanced Fibrosis in NASH

    Targeting Development Decades Insulin Steatosis Because Cirrhosis Fibrosis NASH © 162013Resistance/Diabetes Galectin of Anti-Galectin (fatty effect ofliver) Obesity Therapeutics on inflammation TherapyNASDAQ:GALT In in TheNASH Progression and ability of NASH to reduce existing fibrosis, our clinical

  17. Slide 17: GR-MD-02 NASH Clinical Development Program

    Galectin 2012 Q1 IND Pre-Clinical NASH (timing First Top Fast Endpoints: Phase Design: Primary Secondary © 2013 Q2 line (FDA; Track patient 2013 Development 1Q3 2to Galectin Randomized, Endpoint: results Therapeutics Trial: NASH be Q4 proceed Designation Serum 2014 Endpoints: Completed enrolled dete

  18. Slide 18: Galectin Competition in NASH

    Galectin Competition Most Minimal Raptor Intercept Mochida: Few Gilead: Galectin: © 2013 companies drugs Pharmaceuticals: Lysyl Galectin or Therapeutics Pharmaceuticals: GR-MD-02 ethyl boarder ininoxidase-like-2 development NASH icosapentate are Therapeutics line focused results cysteamine Obetichol

  19. Slide 19: Cancer Therapy

    Science Galectin Liver Immune Mechanism Regulatory Competitive © 2013Fibrosis Galectin of Enhancement Therapeutics Function Inhibitors Galectins and of Positioning Action Clinical Therapeutics in Plan Cancer NASDAQ:GALT Therapy 19

  20. Slide 20: Galectins Have Multiple Roles in Tumor Pathogenesis

    Galectin Metastasis: Tumor Angiogenesis The © 202013 Vast “Galectin cell immunity Galectin Therapeutics Majority invasion: cell Effect” invasion has Therapeutics of Cancers extracellular recently protects and migration been Secrete tumors NASDAQ:GALT matrix shown from Large adhesion to immune Amount

  21. Slide 21: Tumors Evade the Immune System Using Galectin-3

    Tumors Galectin Galectin-3 Treatment To Experiments Belgium © 212013 review NASDAQ:GALT Galectin Evade in Therapeutics data with secreted collaboration performed and the GM-CT-01 Therapeutics Immune literature by tumor by with blocks Dr. System in Galectin cells Pierre more Galectin-3 binds Using de

  22. Slide 22: GM-CT-01 Phase 2a Melanoma Trial

    Galectin Preclinical Melanoma Design: response Group More © 222013 NASDAQ:GALT information 2Galectin Two patients Therapeutics by efficacy “Proof imaging stageTherapeutics have available ofand Phase Concept” Study additional clinical 2a on site: (6x2 Trial: clinicaltrials.gov: safety Ludwig injectio

  23. Slide 23: GM-CT-01 Cancer Development Program

    Tumor Galectin 2012 Q1 Phase Top GM-CT-01 Stage At Continue Consider Seek Pursue *Conducted ** © 23 2013 Estimate conclusion NASDAQ:GALT Q2 line 2013 partnership 2I/II Immune Q3 Partnering Galectin TBD results Therapeutics Phase to Melanoma Q4 2014 of Stage inof Stage Q1 Belgium in Enhancement Stage

  24. Slide 24: Enhancing Immune Function in Cancer Immunotherapy

    Immune Galectin Enhancing Two Dendritic T-cell Our While The © 242013 NASDAQ:GALT compound tumor agents activator tumor Galectin Enhancement Therapeutics cell vaccine the have vaccines vaccine: ability (CTLA4 reverses Therapeutics been market of are Provenge® by approved receptor the the patient Blo

  25. Slide 25: Key Company Milestones

    Key Galectin NASH 3/1/13: 5/13: Q1 Q2 Top Cancer Phase Five © 252013 NASDAQ:GALT 2014: line Company patients Initiate with 2a FDA Immunotherapy Galectin data Therapeutics Phase Initiate metastatic Advanced provided Phase currently from Milestones: Therapeutics 1Phase Phase NASH 1melanoma OK NASH Fib

  26. Slide 26: Investment Highlights

    Galectin Investment Proprietary First Complex GR-MD-02: GM-CT-01: Validated Pre-clinical Large NASH Enhancing Intellectual Strong Sole No Experienced Management © 2013 licenses in ownership Market and patent class, Galectin Therapeutics carbohydrate Science liver the Property models Compounds Highli

  27. Slide 27: Appendix

    Galectin © Appendix 27 NASDAQ:GALT 2013 Galectin Therapeutics Therapeutics

  28. Slide 28: Experienced Management Team

    Galectin Experienced Peter in GlaxoSmithKline Harold Therapeutics Eliezer Koor Thomas PricewaterhouseCoopers, J. Over Solvay © 28 NASDAQ:GALT 2013 Rex liverBiotechnologies, 25 30 10 20 G. Horton disease H. Pharmaceuticals Pharmaceuticals, Zomer, Galectin A. years Therapeutics Traber, Shlevin, McGaul

  29. Slide 29: Galectin Protein Structure

    CONFIDENTIAL TYPE T 3 Carbohydrate Galactose-containing One-CRD Galectines-3 Two-CRD cell–cell cell–matrix lattice outside Inside signal Galectin © 29 NASDAQ:GALT wo-CRD 2013STRUCTURE formation transduction cell cell Galectin and Therapeutics Proteins proteins 4,6,8,9,12 galectins 1,2,5,7,10,11,13,1

  30. Slide 30: Rationale for Targeting Galectin Proteins with Complex Carbohydrates

    Galectin Rationale CONFIDENTIAL The Galactomannan glycoproteins Galacto-Rhamnoglucuronate © 30 NASDAQ:GALT 2013 theoretical Galectin Therapeutics for Galectin basis (GM-CT-01) Therapeutics for Protein complex (GR-MD-02) Targeting carbohydrate with Complex drugs is Carbohydrate that terminalAgents ga

  31. Slide 31: Intellectual Property

    Intellectual Galectin GM-CT US Five International GR-MD Composition Method All No © 31 NASDAQ:GALT 2013 intellectual established Composition USGalectin Class of Class issued Therapeutics use Property Patents: of(current property (current in generic matter method Therapeutics of liver NASH matter 14

  32. Slide 32: Galectin Inhibition Mechanisms in NASH

    Inhibition Cause Metabolic Resolution Fibrosis Mediators Glucose Fat Impaired Free Adipocytokines Hyperglycemia T-Cell Lipo-peroxidation Release Quiescent Inflammation ECM Extracellular MMPs Stellate Gal-3 Galectin Scavenger Increases Promotes GR-MD-02 Inhibit Reduce Reduces ? © 32 NASDAQ:GALT Effec

  33. Slide 33: General Approaches to Treating NASH

    Galectins General Treat Obesity Lipid Modulate Protease Bile Anti-Oxidant Anti-collagen Lifestyle, Examples Aramchol Pioglitazone EGS21 GS-9450 Pentoxifylline Obeticolic Colesevelam Vitamin MND-21 Lysyl Cysteamine Can Comments Failed Cholesterol Abandoned Non Liver Intestinal FXR Effective Omega-3 P

  34. Slide 34: Other Galectin Companies

    Galectin Other Galecto LaJolla with Mandel © 34 NASDAQ:GALT 2013 claims companies Pharmaceuticals Galectin Med Biotech Therapeutics for (Oakland, binding AG Therapeutics with (Sweden): galectin galectins; CA): (CA): Truncated inhibitor In Discovery focused Jan. 2012, galectin-3 programs on phase the

  35. Slide 35: Capitalization

    Galectin Capitalization Shares Common Preferred Preferred: Warrants: *Options ** *** © Total Management, 10X Series Other Publicly Public Exercise 2013 Weighted Weighted Fund Outstanding Warrants** Warrants Float A C(9/30/12) Galectin Traded Outstanding*** Therapeutics Shares Shares Stock Shares Ser

Galectin Therapeutics — Investor Presentation (March 2013) on 6ix